|
Offshore allure. (Labuan, Malaysia's economy)(includes related article)
The Banker
|
June 1, 1995|
|
COPYRIGHT 1995 FT Business. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
(Hide copyright information)
Copyright
|
The tiny island off the coast of Borneo aims to become "the pearl of the South China Sea".
Labuan, a 92-sq km island off the coast of Borneo in East Malaysia, was once famous for its smuggling, its pirates and its Sunday cockfights. Now, if the ideas of Malaysia's planning gurus are carried through, the buzz and whirl of finance will reverberate as Labuan emerges as one of the latest, most exotic, international offshore financial centres (IOFC).
The island became an IOFC in 1990. Progress appears slow: there is little sign of dynamic financial activity. No Wall ...
|
Isis Acquires Symphony GenIsis.
PR Newswire
; ISIS 301012 now under Isis' ownership in preparation for partnering CARLSBAD, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. , today announced its purchase of all of the...
|
|
|
ISIS BEGINS PHASE III CLINICAL TRIALS OF ANTISENSE COMPOUND TO TREAT CMV RETINITIS IN PATIENTS WITH AIDS
PR Newswire
; ...Calif., Dec. 14 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...controlled, Phase III clinical trials of ISIS 2922, an antisense compound to treat cytomegalovirus...and leads to blindness if not treated. ISIS 2922 is an antisense compound that inhibits...
|
|
|
ISIS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH ZENECA LTD. FOR MANUFACTURE OF NOVEL ANTI-HIV COMPOUND
PR Newswire
; CARLSBAD, Calif., Nov. 16 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) announced...Biochemicals (CRB) business, for the manufacture of Isis' anti-HIV compound, ISIS 5320, a phosphorothioate oligonucleotide, eight...
|
|
|
ISIS 301012 Reduces Atherosclerotic Plaques in Animal Models.
PR Newswire
; Data Confirms That ISIS 301012 Has Potential to Benefit Patients With...April 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced results of a study showing that ISIS 301012 reduced atherosclerotic plaques, apoB...
|
|
|
ISIS 301012 Does Not Interact With Currently Marketed Lipid Lowering Drugs.
PR Newswire
; ...March 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced additional data from clinical studies of ISIS 301012 that continue to broaden the potential...In a drug-drug interaction study, ISIS 301012 did not interact with simvastatin...
|
|
|
Isis to Proceed With Development of ISIS 3521 and ISIS 5132 as Novartis Concludes Participation.
PR Newswire
; CARLSBAD, Calif., Nov. 22 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced today that...will conclude its participation in the development of ISIS 3521 and ISIS 5132, two anticancer compounds, at the completion of...
|
|
Isis Distributed Systems and IONA Technologies announces first shipment of Orbix + Isis; The first fault-tolerant object request broker.
Business Wire
; ...BUSINESS WIRE)--Aug. 14, 1995--Isis Distributed Systems Inc. and IONA Technologies...World, the commercial shipment of Orbix + Isis, the industry's first fault-tolerant Object Request Broker (ORB). Orbix + Isis, a joint development between Isis Distributed...
|
|
ISIS, LILLY ENTER ANTISENSE DEAL WITH POTENTIAL OF $400M-PLUS.(Brief Article)
Magazine article from: BIOWORLD Today
; In the beginning of 2000, Isis Pharmaceuticals Inc. suffered a Phase III...antisense compound for Crohn's disease, ISIS 2302, failing to see significant results. Looking to stay afloat, Isis set about the uncomfortable task of jettisoning...
|
|
|
Isis Begins Phase I/II Trial of Second Generation CMV Retinitis Compound
PR Newswire
; ...Calif., Jan. 6 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced...beginning of Phase I/II clinical trials of ISIS 13312, a compound to treat cytomegalovirus...threatening infection in patients with AIDS. ISIS 13312 is the company's first compound...
|
|
|
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes.
PR Newswire
; ...Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced...SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug...increase glucose excretion, complements Isis' existing pipeline of drugs in development...
|
Find more facts and information related to the
article "Offshore allure. (Labuan, Malaysia's ..."
